SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers.
Lu Z, Mao W, Yang H, Santiago-O'Farrill JM, Rask PJ, Mondal J, Chen H, Ivan C, Liu X, Liu CG, Xi Y, Masuda K, Carrami EM, Chen M, Tang Y, Pang L, Lakomy DS, Calin GA, Liang H, Ahmed AA, Vankayalapati H, Bast RC Jr.
Lu Z, et al. Among authors: santiago o farrill jm.
J Clin Invest. 2022 Jun 1;132(11):e146471. doi: 10.1172/JCI146471.
J Clin Invest. 2022.
PMID: 35642638
Free PMC article.